Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity
by
Katherine L. Mills 1,2,*,
Emma L. Barrett 1,2,3,
Sabine Merz 1,
Julia Rosenfeld 1,
Philippa L. Ewer 1,2,
Claudia Sannibale 1,
Amanda L. Baker 4,
Sally Hopwood 5,
Sudie E. Back 3,
Kathleen T. Brady 3 and
Maree Teesson 1,2
Katherine L. Mills 1,2,*,
Emma L. Barrett 1,2,3,
Sabine Merz 1,
Julia Rosenfeld 1,
Philippa L. Ewer 1,2,
Claudia Sannibale 1,
Amanda L. Baker 4,
Sally Hopwood 5,
Sudie E. Back 3,
Kathleen T. Brady 3 and
Maree Teesson 1,2
1
National Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia
2
Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, Sydney 2052, NSW, Australia
3
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
4
School of Medicine and Public Health, University of Newcastle, Callaghan 2308, NSW, Australia
5
School of Psychology, University of New South Wales, Sydney 2052, NSW, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Hans-Jürgen Möller
J. Clin. Med. 2016, 5(11), 101; https://doi.org/10.3390/jcm5110101
Received: 31 August 2016 / Revised: 26 October 2016 / Accepted: 8 November 2016 / Published: 15 November 2016
(This article belongs to the Special Issue Post-Traumatic Stress Disorder 2016)
This paper examines factors associated with change in PTSD symptom severity among individuals randomised to receive an integrated exposure-based psychotherapy for PTSD and substance dependence–Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE). Outcomes examined include change in PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS), and the reliability and clinical significance of change in PTSD symptom severity. Factors examined include patient baseline characteristics, treatment characteristics, and events over follow-up. The mean difference in CAPS score was 38.24 (SE 4.81). Approximately half (49.1%) demonstrated a reliable and clinically significant improvement in PTSD symptom severity. No one was classified as having demonstrated clinically significant worsening of symptoms. Three independent predictors of reductions in PTSD symptom severity were identified: baseline PTSD symptom severity (β 0.77, SE 0.23, p = 0.001), number of traumas experienced prior to baseline (β −0.30, SE 0.15, p = 0.049), and number of sessions attended (β 2.05, SE 0.87, p = 0.024). The present study provides further evidence regarding the safety of the COPE treatment and factors associated with improvement in PTSD symptom severity. The identification of only a small number of predictors of the outcome points to the broad applicability of the COPE treatment to PTSD and substance use disorder (SUD) patients.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Mills, K.L.; Barrett, E.L.; Merz, S.; Rosenfeld, J.; Ewer, P.L.; Sannibale, C.; Baker, A.L.; Hopwood, S.; Back, S.E.; Brady, K.T.; Teesson, M. Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity. J. Clin. Med. 2016, 5, 101.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
